Literature DB >> 11359754

Impaired cardiac adrenergic innervation assessed by MIBG imaging as a predictor of treatment response in childhood dilated cardiomyopathy.

P Acar1, P Merlet, L Iserin, D Bonnet, D Sidi, A Syrota, J Kachaner.   

Abstract

OBJECTIVE: To evaluate the prognostic value of metaiodobenzylguanidine (MIBG) imaging in childhood cardiomyopathy.
DESIGN: Prospective cohort study.
SETTING: Tertiary referral centre. PATIENTS: 40 children (21 boys, 19 girls; mean (SD) age, 7.0 (5.6) years) with heart failure resulting from idiopathic dilated cardiomyopathy (n = 23) or various other disorders (n = 17).
METHODS: At the initial examination, cardiac (123)I-MIBG uptake and release, circulating noradrenaline (norepinephrine) concentration, x ray cardiothoracic ratio, and echocardiographic variables were recorded. Cardiac MIBG uptake was obtained by measuring the heart to mediastinum activity ratio on the planar image obtained four hours after MIBG injection. MIBG washout rate was evaluated using relative decrease in cardiac activity measured at 20 minutes and four hours. Patients were treated with angiotensin converting enzyme inhibitors, diuretics, and digitalis, and were followed up for 12 (10) months. Fifteen patients did not respond to medical treatment (12 heart transplants; three deaths), and 25 did respond (improved or stable).
RESULTS: Cardiac MIBG uptake was positively correlated with x ray cardiothoracic index (r = 0.55, p = 0.0008) and echocardiographic left ventricular fractional shortening (r = 0.68, p < 0.0001). Among all the clinical and laboratory variables tested, multivariate discriminant analysis showed that the only independent predictor of an unfavourable outcome was a low MIBG uptake (p < 0.001). Survival curves had a mean threshold value of 1.54 for MIBG uptake.
CONCLUSIONS: Impaired cardiac adrenergic innervation is strongly related to adverse outcome in children with dilated cardiomyopathy, independently of the aetiology. MIBG imaging may help to stratify risk in such patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11359754      PMCID: PMC1729756          DOI: 10.1136/heart.85.6.692

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  42 in total

1.  Clinical profile of congestive cardiomyopathy in children.

Authors:  S C Chen; S Nouri; I Balfour; S Jureidini; R S Appleton
Journal:  J Am Coll Cardiol       Date:  1990-01       Impact factor: 24.094

2.  Congestive cardiomyopathy in children.

Authors:  W G Guntheroth
Journal:  J Am Coll Cardiol       Date:  1990-01       Impact factor: 24.094

3.  [Myocardial noradrenaline content: a factor not considered up to now for the prognosis of patients with dilated cardiomyopathy].

Authors:  J Schofer; A Tews; H Rühwedel; P E Reimitz; D G Mathey
Journal:  Z Kardiol       Date:  1989-06

4.  Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration.

Authors:  T S Rector; M T Olivari; T B Levine; G S Francis; J N Cohn
Journal:  Am Heart J       Date:  1987-07       Impact factor: 4.749

5.  Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.

Authors:  D J Sahn; A DeMaria; J Kisslo; A Weyman
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

6.  Decreased adrenergic neuronal uptake activity in experimental right heart failure. A chamber-specific contributor to beta-adrenoceptor downregulation.

Authors:  C S Liang; T H Fan; J T Sullebarger; S Sakamoto
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

7.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.

Authors:  J N Cohn; T B Levine; M T Olivari; V Garberg; D Lura; G S Francis; A B Simon; T Rector
Journal:  N Engl J Med       Date:  1984-09-27       Impact factor: 91.245

8.  Determinants of clinical response and survival in patients with congestive heart failure treated with captopril.

Authors:  M A Creager; D P Faxon; J L Halperin; C D Melidossian; C H McCabe; E C Schick; T J Ryan
Journal:  Am Heart J       Date:  1982-11       Impact factor: 4.749

9.  Dilated cardiomyopathy in infants and children.

Authors:  M L Griffin; A Hernandez; T C Martin; D Goldring; R M Bolman; T L Spray; A W Strauss
Journal:  J Am Coll Cardiol       Date:  1988-01       Impact factor: 24.094

10.  Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group.

Authors:  A Gradman; P Deedwania; R Cody; B Massie; M Packer; B Pitt; S Goldstein
Journal:  J Am Coll Cardiol       Date:  1989-09       Impact factor: 24.094

View more
  6 in total

1.  Echocardiographic predictors of adverse clinical events in children with dilated cardiomyopathy: a prospective clinical study.

Authors:  C J McMahon; S F Nagueh; R S Eapen; W J Dreyer; I Finkelshtyn; X Cao; B W Eidem; L I Bezold; S W Denfield; J A Towbin; R H Pignatelli
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

2.  Use of 123I-MIBG scintigraphy to assess the impact of carvedilol on cardiac adrenergic neuronal function in childhood dilated cardiomyopathy.

Authors:  Christophe Maunoury; Philippe Acar; Daniel Sidi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-23       Impact factor: 9.236

3.  Outcome Predictors for Pediatric Dilated Cardiomyopathy: A Systematic Review.

Authors:  Jorge A Alvarez; James D Wilkinson; Steven E Lipshultz
Journal:  Prog Pediatr Cardiol       Date:  2007-09-01

4.  Idiopathic dilated cardiomyopathy in children; Natural history and predictors of prognosis.

Authors:  Inas Abdullsattar Saad
Journal:  Libyan J Med       Date:  2007-09-01       Impact factor: 1.657

5.  Symptoms of dysautonomia, sleep disturbance, and abnormal cognition in pediatric heart failure.

Authors:  J Menteer; M S Woo; J D So; A B Lewis
Journal:  Pediatr Cardiol       Date:  2007-07-26       Impact factor: 1.838

6.  Interobserver variability of heart-to-mediastinum ratio in I-123 MIBG sympathetic imaging.

Authors:  Ben F Bulten; Roel L F van der Palen; Hanneke W M van Laarhoven; Livia Kapusta; Annelies M C Mavinkurve-Groothuis; Lioe-Fee de Geus-Oei
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.